Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System

Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.